Voyager Therapeutics Revenue 2014-2022 | VYGR

Voyager Therapeutics revenue from 2014 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Voyager Therapeutics Annual Revenue
(Millions of US $)
2021 $37
2020 $171
2019 $104
2018 $8
2017 $10
2016 $14
2015 $17
2014 $
2013 $
Voyager Therapeutics Quarterly Revenue
(Millions of US $)
2022-03-31 $1
2021-12-31 $28
2021-09-30 $1
2021-06-30 $1
2021-03-31 $7
2020-12-31 $7
2020-09-30 $118
2020-06-30 $29
2020-03-31 $18
2019-12-31 $33
2019-09-30 $20
2019-06-30 $46
2019-03-31 $5
2018-12-31 $2
2018-09-30 $2
2018-06-30 $3
2018-03-31 $1
2017-12-31 $6
2017-09-30 $1
2017-06-30 $1
2017-03-31 $1
2016-12-31 $2
2016-09-30 $3
2016-06-30 $4
2016-03-31 $5
2015-12-31 $5
2015-09-30 $5
2015-06-30 $5
2015-03-31 $3
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.245B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00